Physician profile
Saju Eapen
NPI 1649249699
$7,742.27
in general payments reported to CMS, 2019-2025
28 companies · $1,574 in 2025
The $1,574 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $636 · 2021: $655 · 2022: $1,117 · 2023: $1,183 · 2024: $1,912 · 2025: $1,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,492 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.50 |
| Education | $177.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,351.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,178.45 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,149.35 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $792.76 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $620.51 | 2019-2025 | Xolair |
| Pfizer INC. | $569.38 | 2019-2025 | |
| Csl Behring | $405.02 | 2020-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $222.91 | 2020-2025 | Cuvitru, Hyqvia |
| Novartis Pharmaceuticals Corporation | $181.24 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $176.98 | 2022-2025 | |
| Pharming Healthcare, INC. | $175.43 | 2019-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $152.33 | 2021-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.34 | 2019-2021 | |
| Optinose US, INC. | $108.85 | 2020-2025 | |
| Blueprint Medicines Corporation | $101.09 | 2023-2024 | Ayvakit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $95.91 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $70.75 | 2021-2022 | |
| Shire North American Group INC | $57.09 | 2019 | |
| Kaleo, INC. | $47.53 | 2020-2023 | Auvi-Q |
| Galderma Laboratories, L.P. | $27.46 | 2025 | Nemluvio |
| Incyte Corporation | $23.73 | 2022 | |
| Cycle Pharmaceuticals INC | $20.22 | 2024 | Sajazir |
| Ionis Pharmaceuticals, INC. | $18.61 | 2025 | Donidalorsen |
| Merck Sharp & Dohme LLC | $18.60 | 2023 | |
| Mylan Specialty L.P. | $17.75 | 2020 | |
| Octapharma USA, INC. | $16.51 | 2025 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $15.04 | 2025 | Neffy |
| Horizon Therapeutics Plc | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saju Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.